Experience in using biosimilars in IVF programs with donor oocytes in protocols with micronized progesterone
Abshekenova A.T. Rybina A.N. Askar E. Karibaeva S.K. Valiev R.K. Lokshin V.N.
1 April 2024Kaz Med Print LLP
Reproductive Medicine (Central Asia)
2024#2024Issue 127 - 33 pp.
Relevance: Stimulation of oocyte donors superovulation occupies a key place in the development of assisted reproduction technology (ART) in general. Oocyte donation programs involve young and healthy women undergoing severe ovarian stimulation protocols to obtain good-quality oocytes. Advances in recombinant DNA technology led to the development of recombinant follitropin alfa. The study aimed to evaluate the effectiveness of the biosimilar follitropin alfa in the superovulation stimulation cycles of oocyte donors in comparison with the original medication in Progestin primed ovarian stimulation (PPOS) protocols. Materials and Methods: A prospective cohort study included 25 oocyte donors who underwent superovulation induction. The first group consisted of 25 oocyte donors in whose superovulation was stimulated with a bio-analogue of follitropin alfa. The second group (control) included the same 25 donors stimulated with the original rFSH drug. The resulting donor oocytes were fertilized using Intra-Cytoplasmic Sperm Injection (ICSI) or frozen. The programs result was determined by taking a blood test for b-hCG 14 days after embryo transfer. Results: The number of mature oocytes in the study groups did not differ significantly, amounting to 20.6 ± 1.1 in group 1 and 21.2 ± 1.3 in group 2. The average number of fertilized oocytes in group 1 was 5.6 ± 0.8, and in group 2 – 6.1 ± 1.1; thus, the fertilization rate in the two groups did not differ (67.5% in group 1 vs 79.2% in group 2, р> 0,05). The blastulation rate (49.1% in group 1 and 52.2% in group 2) did not differ significantly in both the biosimilar group and the original medication. The Top Quality Blastocysts in Group 1 were 1.5 ± 0.7 (55%) vs 1.8 ± 0.5 (48%) in Group 2. At that, the cumulative pregnancy rate in both groups did not differ statistically significantly. Conclusion: Biosimilars were not inferior to the original medication in terms of the proportion of mature oocytes in oocyte donors. The studys results confirm that biosimilars demonstrate favorable and comparable efficacy to the original medication in oocyte maturation in IVF/ICSI cycles.
biosimilars , Intra-Cytoplasmic Sperm Injection (ICSI) , IVF , micronized progesterone , PPOS , progestin-primed ovarian stimulation
Text of the article Перейти на текст статьи
International Clinical Center for Reproductology “PERSONA,”, Almaty, Kazakhstan
Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan
International Clinical Center for Reproductology “PERSONA
Asfendiyarov Kazakh National Medical University
10 лет помогаем публиковать статьи Международный издатель
Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026